Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]

$ 20.50

4.9 (670) In stock

U.S. Patent Application 20190241896 for Modulators Of Dnm2 Expression

Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

Shuling GUO, Director, Doctor of Philosophy, Ionis Pharmaceuticals, Carlsbad, Antisense Drug Discovery

Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]

Frontiers High-Throughput Native Mass Spectrometry Screening in Drug Discovery

Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy

JCI Insight - Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin

Isomer Separation with Vocus Ion Mobility Spectrometry - TOFWERK

Brett P. Monia's research works Ionis Pharmaceuticals, Carlsbad and other places

IJMS, Free Full-Text

JCI Insight - Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin

Shuling GUO, Director, Doctor of Philosophy, Ionis Pharmaceuticals, Carlsbad, Antisense Drug Discovery

A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect

Clemmer Group: Indiana University Bloomington